Amadei (Gsk): “San Polo a center of excellence”

“Our site is an excellence for difficult biotechnological products, both sterile liquid and lyophilized, but also solid oral products with high containment, which means that they have particularly delicate handling characteristics both for the product itself, but also for the operators who work every day in contact with the drug and we have the technologies and skills to be able to carry them out from research to the final market “. Thus Maria Chiara Amadei, plant manager and CEO of Gsk Manufacturing, on the sidelines of the ‘Innovation and value production’ roadshow at the San Polo di Torrile plant, Parma. If Emilia Romagna in the last 10 years has had a real boom in pharmaceutical exports, + 108%, it also owes it to centers such as the GSK in San Polo. “We produce for more than 100 markets around the world and our drugs are introduced from the San Polo plant – continued Amadei – we have different therapeutic areas, on the autoimmune system, on the respiratory system, on HIV and oncology and not least the antibody monoclonal which is used for the treatment of Covid-19 “. In Italy, 67,000 people work in 200 companies in the pharmaceutical sector (90% graduates or graduates). Over the last 5 years, the under 35s have increased by 16% and have permanent contracts for about 80%. And San Polo is no exception. “Ours is an extremely young company, the average age is 43 and the thing I am proud of – concluded Amadei – is that we have great talents: they are people who believe in our mission, they work to achieve the objectives that we have set ourselves. I would therefore speak of investment in young people, but above all in the talents that allow us to be a center of excellence in the world “.